polyangiitis


Also found in: Medical.
Translations

polyangiitis

n poliangeítis f; microscopic — poliangeítis microscópica
Mentioned in ?
References in periodicals archive ?
It was granted the same status by the US FDA for the treatment of Eosinophilic Granulomatosis with Polyangiitis. It is a monoclonal antibody and has been designed to directly bind to the IL-5 receptor alpha on eosinophils.
The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G.
In November 2018, the FDA granted ODD for Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) and also granted ODD for the treatment of hypereosinophilic syndrome (HES) in February 2019.
ABP 798 is being developed as a biosimilar candidate to Rituxan, an anti-CD20 monoclonal antibody that is approved in many regions for the treatment of adult patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, moderate-to-severe rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
(NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE[TM] (rituximab-pvvr), a biosimilar to Rituxan[R] (rituximab), for the treatment of adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
M2 PRESSWIRE-August 8, 2019-: Microscopic Polyangiitis (MPA) Pipeline Review, H1 2019 Report Featuring Celltrion, ChemoCentryx, InflaRx, Teijin Pharma
Food and Drug Administration (FDA) has accepted the company's supplemental Biologies License Application (sBLA) and granted Priority Review for the use of Rituxan[R] (rituximab), in combination with glucocorticoids (GCC), for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children two years of age and older.
Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement.
Granulomatosis with polyangiitis (GPA) (formerly named Wegener's granulomatosis) is an uncommon kind of systemic vasculitis involving small-to-medium sized vessels, and categorized as ANCA-associated vasculitities with the presence of anti-neutrophil cytoplasm antibodies (1).
CVT can also occur secondary to conditions or therapies which create a prothrombotic state: inflammatory bowel diseases (Crohn's disease and ulcerative colitis), infections (sinusitis), trauma, nephrotic syndrome, liver cirrhosis, neoplasms, autoimmune diseases (systemic lupus erythematosus, granulomatosis with polyangiitis, Behcet's disease), sarcoidosis, anemia, pregnancy and puerperal period, high altitudes, use of drugs: oral contraceptives, erythropoietin, tamoxifen, corticosteroids, thalidomide, asparaginase [3].
"We look forward to continuing to leverage our experience and expertise in biotechnology to bring more biosimilars to patients." ABP 798 is being developed as a biosimilar candidate to rituximab, a CD20-directed cytolytic antibody that is approved in many regions for the treatment of adult patients with moderate-to-severe rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
Wegener granulomatosis (granulomatosis with polyangiitis)